Harout Semerjian
Principal executive officer pay for Harout Semerjian, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Grouped by exact name match across filings; distinct people sharing a name would be merged — flag it and we'll split them.
GLYCOMIMETICS INC (GLYC) FY2023–FY2024
Aligned: pay fell with the stockCAP $1,726,797→$16,200 while $100 invested went $77.89→$8.22
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $2.4M | $1.7M |
| FY2024 | $2.9M | $16,200 |
The company's "$100 invested" index ran $77.89 at FY2023 → $8.22 by FY2024 — an annualized return of -89.4%.
GERON CORP (GERN) FY2025–FY2025
Tracked peersTSR $83.00→$83.00 vs peer group $125.00→$125.00 (FY2025–FY2025)
Aligned: pay fell with the stockCAP $10,176,355→$10,176,355 while $100 invested went $83.00→$83.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2025 | $10.2M | $10.2M |
The company's "$100 invested" index ran $83.00 at FY2025 → $83.00 by FY2025.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -89.4%/yr at GLYC ( FY2023–FY2024). See the CEO track-record ranking for context.
All disclosed tenures: 1 years across 2 companies, $100 → $10.55 combined (-89.4%/yr). Chained through each company's own "$100 invested" index, one stint after the next — still bounded by disclosure, which began with fiscal year 2022, not by the full career.